(Q41386447)

30 September 2017

title

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer (English)

1 reference

30 September 2017

1 reference

1 reference

1 reference

15

Akihiko Ueda

0 references

Ken Yamaguchi

14

object named as

Ken Yamaguchi

0 references

Tasuku Honjo

20

object named as

Tasuku Honjo

1 reference

30 September 2017

Noriomi Matsumura

11

0 references

Ikuo Konishi

21

object named as

Ikuo Konishi

1 reference

30 September 2017

13

Tsukasa Baba

1 reference

30 September 2017

1

Junzo Hamanishi

1 reference

30 September 2017

12

Kaoru Abiko

1 reference

30 September 2017

2

Masaki Mandai

1 reference

30 September 2017

Takafumi Ikeda

3

1 reference

30 September 2017

Manabu Minami

4

1 reference

30 September 2017

Atsushi Kawaguchi

5

1 reference

30 September 2017

Toshinori Murayama

6

1 reference

30 September 2017

Masashi Kanai

7

1 reference

30 September 2017

Yukiko Mori

8

1 reference

30 September 2017

Shigemi Matsumoto

9

1 reference

30 September 2017

Shunsuke Chikuma

10

1 reference

30 September 2017

Yuko Hosoe

16

1 reference

30 September 2017

Satoshi Morita

17

1 reference

30 September 2017

Masayuki Yokode

18

1 reference

30 September 2017

Akira Shimizu

19

1 reference

30 September 2017

language of work or name

English

0 references

publication date

8 September 2015

1 reference

Journal of Clinical Oncology

30 September 2017

published in

1 reference

30 September 2017

volume

33

1 reference

30 September 2017

issue

34

1 reference

30 September 2017

page(s)

4015-4022

1 reference

https://opencitations.net/index/coci/api/v1/citations/10.3322/CAAC.20006

30 September 2017

cites work

Cancer statistics, 2009

1 reference

28 May 2022

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Management strategies for recurrent platinum-resistant ovarian cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Inhibitory B7-family molecules in the tumour microenvironment

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Integrated genomic analyses of ovarian carcinoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Ovarian cancer, version 2.2013.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Cancer immunotherapy comes of age

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Cancer immunoediting: from immunosurveillance to tumor escape

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Immunotherapy for ovarian cancer: what's next?

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Nivolumab plus ipilimumab in advanced melanoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

PD-1 and its ligands in tolerance and immunity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1200/JCO.2015.62.3397

Identifiers

DOI

10.1200/JCO.2015.62.3397

1 reference

30 September 2017

1 reference